ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Companyâs lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
äŒæ¥ã³ãŒã- -
äŒç€Ÿå- -
äžå Žæ¥- -
æé«çµå¶è²¬ä»»è
ãCEOã- -
åŸæ¥å¡æ°- -
蚌åžçš®é¡- -
æ±ºç®ææ«- -
æ¬ç€Ÿæåšå°- -
éœåž- -
蚌åžååŒæ- -
åœ- -
éµäŸ¿çªå·- -
é»è©±çªå·- -
ãŠã§ããµã€ã- -
äŒæ¥ã³ãŒã- -
äžå Žæ¥- -
æé«çµå¶è²¬ä»»è
ãCEOã- -